Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease

被引:131
作者
Bogart, LM
Catz, SL
Kelly, JA
Benotsch, EG
机构
[1] Kent State Univ, Dept Psychol, Kent, OH 44242 USA
[2] Med Coll Wisconsin, Dept Psychiat & Behav Med, Ctr AIDS Intervent Res, Milwaukee, WI 53226 USA
关键词
HIV/AIDS; antiretroviral treatment; medical decision making; adherence; attitudes;
D O I
10.1177/0272989X0102100104
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
New medications for HIV reduce mortality and morbidity but require strict adherence. Thus, physicians treating HIV-positive patents must weigh both disease severity and likelihood of adherence when deciding whether to start patents on treatment. A national sample of 495 physicians surveyed via mail responded to clinical scenarios depicting HIV-positive patents and indicated whether they would start patients on medication (response rate = 53%). Scenarios varied on the patient characteristics of gender, disease severity, ethnicity, and risk group. Physicians predicted that patients with less severe disease, former injection drug users, and African American men would be less likely to adhere. Perceived adherence and disease severity influenced treatment decisions. Results are discussed in the context of attitudes about minority groups and injection drug users, which may influence adherence judgments in practice settings. Psychological research to identify better methods of predicting medication adherence may serve to inform medical decision making.
引用
收藏
页码:28 / 36
页数:9
相关论文
共 38 条
[1]   When should we delay highly active antiretroviral therapy? [J].
Bangsberg, DR ;
Moss, A .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1999, 14 (07) :446-448
[2]  
Bassetti S, 1999, J ACQ IMMUN DEF SYND, V21, P114
[3]   Protease inhibitor use among a community sample of people with HIV disease [J].
Bing, EG ;
Kilbourne, AM ;
Brooks, RA ;
Lazarus, EF ;
Senak, M .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 20 (05) :474-480
[4]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[5]  
Bogart LM, 2000, J ACQ IMMUN DEF SYND, V23, P396
[6]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[7]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[8]  
*CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43
[9]   PHYSICIAN CHARACTERISTICS ASSOCIATED WITH DECISIONS TO WITHDRAW LIFE-SUPPORT [J].
CHRISTAKIS, NA ;
ASCH, DA .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1995, 85 (03) :367-372
[10]  
DEEKS SG, 1997, P 37 INT C ANT AG CH